Takeda acquires selected international rights to AMAG's anaemia product Feraheme
This article was originally published in Scrip
AMAG Pharmaceuticals has licensed its anaemia product Feraheme (ferumoxytol) to Takeda for several major markets worldwide, in an alliance worth up to $280 million in upfront, development and commercial milestone payments to the US firm.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.